| 英文摘要 |
Psychiatric education and clinical practice show that fi rst-generation antipsychotics (FGAs) should be carefully monitored for the drug induced- movement disorders including acute dystonia, parkinsonian symptoms, tardive dyskinesia, neuroleptic malignant syndrome (NMS), and akathisia. Previous reports show that ambient temperature, high speed in dose escalation of FGAs, and dehydration can put patients into higher rsik of developing NMS. Second-generation antipsychotics (SGAs) also have side effects of metabolic syndrome, rhabdomyolysis, but not NMS itself. According to DSM-IV-TR, research diagnostic criteria of NMS (333.92) are: (A) The development of severe muscle rigidity and elevated temperature associated with use of neuroleptic medication. (B) Two (or more) of the following: diaphoresis, dyphagia, tremor, incontinence, changes in level of consciousness ranging from confusion to coma, mutism, tachycardia, elevated or labile blood pressure, leukocytosis,and laboratory evidence of muscle injury (e.g., elevated creatinine phosphokinase, CPK). |
本站僅提供期刊文獻檢索。
